International Cancer Genome Consortium

International Cancer Genome Consortium
Name	International Cancer Genome Consortium
Founded	2008
Type	Consortium
Focus	Cancer genomics
Headquarters	Toronto, Ontario, Canada
Key people	Thomas J. Hudson, Michael Stratton
Website	https://dcc.icgc.org/

International Cancer Genome Consortium. The International Cancer Genome Consortium is a global scientific collaboration established to coordinate large-scale genomic studies of over 50 different cancer types. Its primary mission is to generate comprehensive catalogues of genomic abnormalities in tumors, making the data freely available to the research community worldwide. The initiative represents a monumental effort in biomedical research, bringing together hundreds of scientists from dozens of nations to advance the understanding of carcinogenesis.

Overview

The consortium functions as a decentralized network of independent research projects, each focused on specific tumor types or subtypes. These projects utilize high-throughput DNA sequencing technologies to analyze both the genome of tumors and matched normal tissues from thousands of patients. The overarching aim is to identify all the genetic mutations involved in the development and progression of major forms of cancer, including breast cancer, lung cancer, and colorectal cancer. This systematic approach provides an unprecedented view of the molecular basis of the disease, supporting the development of new diagnostics and therapeutics.

History and formation

The concept for the consortium emerged from a series of workshops and discussions in 2007, involving leading scientists and funding agencies. It was formally launched in 2008 following a planning meeting in London attended by representatives from multiple countries, including Canada, the United Kingdom, the United States, and China. Key architects of the initiative included Thomas J. Hudson of the Ontario Institute for Cancer Research and Michael Stratton of the Wellcome Trust Sanger Institute. The model was inspired by the success of previous large-scale genomics projects like the Human Genome Project and The Cancer Genome Atlas.

Scientific goals and projects

The primary scientific goal is to systematically identify somatic mutations, including single nucleotide variants, copy number alterations, and structural rearrangements, across a wide spectrum of cancers. Each member project commits to sequencing a minimum of 500 samples per tumor type, following standardized protocols for sample collection, DNA extraction, and data analysis. Major projects have focused on cancers such as pancreatic cancer led by the Australian Pancreatic Cancer Genome Initiative, liver cancer studied by teams in Japan, and pediatric cancers investigated by the St. Jude Children's Research Hospital. The data encompasses multiple molecular levels, integrating genomics with epigenomics and transcriptomics.

Organizational structure and members

The consortium operates through a steering committee comprising principal investigators from each member project and representatives from funding organizations. The central coordination is managed by the International Cancer Genome Consortium Data Coordination Centre located in Toronto. Membership includes over 70 project teams from more than 15 jurisdictions, such as the European Union's International Cancer Genome Consortium-International Cancer Genome Consortium, India's Indian Cancer Genome Atlas, and France's Institut Gustave Roussy. Key participating institutions span the globe, including the Broad Institute, the German Cancer Research Center, and the Riken institute in Japan.

Data access and policies

A foundational principle is rapid and pre-publication data release to the global scientific community. All genomic data is deposited in a centralized repository, the International Cancer Genome Consortium Data Portal, which is managed by the European Bioinformatics Institute and the Ontario Institute for Cancer Research. Access is open to all researchers who agree to the consortium's data use policies, which are designed to protect patient privacy and comply with ethical review board approvals from each participating institution. The data release follows the Fort Lauderdale Agreement and Toronto Statement guidelines to promote collaborative science.

Impact and legacy

The consortium has had a profound impact on the field of oncology, generating foundational resources that have accelerated cancer research globally. Its data has been instrumental in identifying new cancer genes, understanding mutational signatures caused by factors like tobacco or UV radiation, and informing the development of targeted therapies. The project's legacy includes the establishment of common standards for genomic data sharing and analysis. It has also paved the way for successor initiatives such as the International Cancer Genome Consortium-ARGO and Pan-Cancer Analysis of Whole Genomes project, which continue to build upon its original mission.

Category:Medical and health organizations Category:Cancer research organizations Category:Genomics organizations Category:International scientific organizations